InVera Medical, the developers of the InVera™ device – a less-invasive, effective, pain-free and faster minimally invasive endovenous medical device treatment for all chronic venous disease patients, proudly announce the promotion of Dr. Aisling O’Sullivan to the position of Vice President for Quality Assurance and Regulatory Affairs.
Aisling has been an invaluable asset to InVera Medical since joining the company in 2021. Her dedication, expertise, and commitment to ensuring the highest standards of quality and regulatory compliance have played a crucial role in the success and growth of the organisation.
In her new role, Aisling will lead the Quality Assurance and Regulatory Affairs teams, overseeing and enhancing processes to maintain and exceed industry standards. Her responsibilities will include developing and implementing strategies to ensure compliance with regulatory requirements, optimising quality management systems, and fostering a culture of continuous improvement throughout the organisation.
Commenting on the announcement, Stephen Cox, CEO, InVera Medical, stated, “We are thrilled to announce Aisling’s well-deserved promotion to Vice President for Quality Assurance and Regulatory Affairs. Her extensive experience and unwavering commitment to quality and compliance makes her the ideal leader for this critical role. We are confident that under her guidance, InVera Medical will continue to set the highest standards in the industry.”
With over 20 years’ experience navigating complex regulatory landscapes and implementing effective quality assurance measures, Aisling has led quality and regulatory teams, resulting in multiple new devices worldwide. Before joining InVera Medical, she held various positions at the National Standards Authority of Ireland, Omega Pharma, XBolt Orthopaedics, OrthoXel, Cook Medical, and RQM+. She holds a PhD in Microbiology from University College Cork, and a BSc Biotechnology from Dublin City University.
InVera Medical looks forward to continued success under Aisling’s leadership, reinforcing the company’s commitment to delivering innovative and high-quality healthcare solutions.
*Investigational device not for sale in US or any international markets.
For more information, please contact email@example.com
Follow us on social media: